Skip to main content
. Author manuscript; available in PMC: 2016 Dec 14.
Published in final edited form as: Cancer Cell. 2015 Dec 14;28(6):773–784. doi: 10.1016/j.ccell.2015.11.006

Figure 7. NAMPT inhibitors inhibit growth of IDH1 mutant xenograft tumors.

Figure 7

(A) SCID mice implanted with HT1080 (IDH1R132C) cells in the flank were randomly assigned to intraperitoneal injections (4 days/week) of FK866 (30 mg/kg, n=6) or vehicle (n=6). Day 0 (treatment initiation) was the baseline. (B) Hematoxylin and eosin (H&E) and Ki-67 staining of HT1080 xenograft tissues. Ki-67 staining index: 63.5 ± 10.3 % (vehicle, left) vs 7.7 ± 4.8% (FK866, right) p=.001. Scale bars, 100μm. (C) Kaplan-Meier estimates of survival by treatment. SCID mice intracerebrally implanted with 2×105 MGG152 cells were randomly assigned to oral gavage (1/week) of either GMX1778 (250 mg/kg, n=6) or vehicle (n=6). (D) NAD+ levels in MGG152 orthotopic xenografts measured 24 hr after one dose of GMX1778 (250 mg/kg, black bar) or vehicle (white bar). Bars, +/− SEM, * p<0.05. See also Figure S4.